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Objective:  To  review  the  scientiﬁc  literature  on  pharmaceutical  advertising  aimed  at health  professionals
in  order  to determine  whether  gender  bias  has  decreased  and  the  quality  of  information  in  pharmaceutical
advertising  has  improved  over  time.
Methods:  We  performed  a content  analysis  of original  articles  dealing  with  medical  drug  promo-
tion  (1998-2008),  according  to quality  criteria  such  as (a) the  number,  validity  and  accessibility  of
bibliographic  references  provided  in pharmaceutical  advertising  and  (b)  the  extent  to  which  gender  rep-
resentations  were  consistent  with  the  prevalence  of the  diseases.  Databases:  PUBMED,  Medline,  Scopus,
Sociological  Abstract,  Eric and  LILACS.
Results:  We  reviewed  31 articles  that analyzed  advertising  in medical  journals  from  1975-2005  and  were
published  between  1998  and 2008.  We  found  that the  number  of  references  used  to  support  pharmaceu-
tical  advertising  claims  increased  from  1975  but that  50%  of  these  references  were  not valid.  There  was
a tendency  to depict  men  in paid  productive  roles,  while  women  appeared  inside  the  home  or  in non-
occupational  social  contexts.  Advertisements  for  psychotropic  and  cardiovascular  drugs  overrepresented
women  and  men  respectively.
Conclusions:  The  use  of  bibliographic  references  increased  between  1998  and  2008.  However,  representa-
tion  of traditional  male-female  roles  was  similar  in  1975  and  2005.  Pharmaceutical  advertisements  may
contribute  to  reinforcing  the  perception  that  certain  diseases  are  associated  with  the  most  frequently
portrayed  sex.
© 2011  SESPAS.  Published  by  Elsevier  España,  S.L.  All rights  reserved.
Calidad  de  la  publicidad  de  fármacos  y  sesgos  de  género  en  las  revistas
de  medicina  (1998-2008):  revisión  de  la  literatura  cientíﬁca
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Objetivo:  Revisar  la  literatura  cientíﬁca  sobre  publicidad  farmacéutica  dirigida  a los  profesionales  sani-
tarios  para  determinar  si han disminuido  los  sesgos  de  género  y  ha  mejorado  la  calidad  de  la  información
a  lo  largo  del  tiempo.
Metodología:  Análisis  de  contenido  de  artículos  originales  sobre  publicidad  farmacéutica  en revistas  médi-
cas (1998-2008),  en  relación  con  criterios  de  calidad  como:  a)  número,  validez  y accesibilidad  de  las
referencias  bibliográﬁcas  utilizadas;  b)  consistencia  entre  los sexos  representados  en  la publicidad  de
fármacos  y la  prevalencia  de  la enfermedad.  Bases  de  datos:  PUBMED,  Medline,  Scopus,  Sociological
Abstract,  Eric  y LILACS.
Resultados:  Los  31 artículos  revisados,  publicados  entre  1998  y 2008,  analizan  la  publicidad  en  revistas
médicas  en  el  periodo  1975-2005.  El  número  de  referencias  bibliográﬁcas  aumentó  desde  1975,  pero
el 50%  no  eran  válidas.  Hay  una  tendencia  a la representación  de  los  hombres  desempen˜ando  roles
productivos  remunerados,  mientras  que  las  mujeres  aparecen  dentro  del  ámbito  doméstico  o en  con-
textos no  laborales.  La  publicidad  para  tratamientos  psicótropos  sobrerrepresenta  a  las  mujeres,  y  la de
tratamientos  cardiovasculares  a los  hombres.
Conclusión:  La  frecuencia  de referencias  bibliográﬁcas  aumenta  entre  1998  y  2008,  pero  los  roles  de  género
representados  en 2005  son  similares  a los de  1975.  La  publicidad  farmacéutica  puede  contribuir  a  reforzar
tas  en
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IntroductionDue to the increasingly global and fragmented context in which
they work, physicians are partially dependent on the ﬂow of infor-
mation conveyed through advertising. Marketing strategies work in
two ways: on the one hand, pharmaceutical advertising simpliﬁes
ts reserved.
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essages and thus facilitates understanding of information usually
equiring specialized knowledge; on the other hand, pharmaceu-
ical advertising is both an authority ﬁgure and a stakeholder, as
t is currently the most important source of ﬁnancial support for
edical journals as well as their main form of publicity. Although
ll advertisements have a commercial purpose and thus generally
ow credibility, medicinal drug promotion is an important ﬁlter of
edical knowledge due to its indirect control over the media.1
Marketing strategies target the medical community and, to
ncrease sales, do not always offer neutral information.2–4 To inﬂu-
nce the perceptions and decisions of the physicians at whom such
ublicity is directed, reality is redeﬁned through the use of partial
nd/or biased images of the target and is related to data on the
eneﬁts derived from certain properties of the drug.5 This redeﬁni-
ion is sometimes further accentuated by the use of information in
he advertisement which is not always supported by bibliographic
eferences.6
To provide a basis for a code of conduct in advertising, the
orld Health Organization (WHO) established their Ethical Criteria
or Medicinal Drug Promotion.7 The pharmaceutical advertisement
alidity indicators used refer to the inclusion of approved scientiﬁc
ata, the number of bibliographic references and the accessibility
f these references to physicians, as well as coherence between the
pidemiological data presented in the advertising claims and the
esearch ﬁndings.7 A tendency to increase the amount of scientiﬁc
ata included in medicinal drug promotion according to the WHO
riteria has been observed over time.8,9
However, another marketing strategy used to achieve greater
mpact is the incorporation into advertising of images that segment
he consumer according to socio-demographic characteristics,10
hich may  represent a further problem for validity11,12 when
nconsistent with research ﬁndings.13 Speciﬁcally, the estimated
revalence of a disease among groups at risk occasionally seems
xaggerated and thus misleading. Furthermore, the potential pop-
lation base that could beneﬁt from the medication is broadened
hrough the use of inappropriate frames that include non-risk
roups, to whom the therapeutic indications do not apply. This
henomenon is known as disease mongering.1,14
As a ﬁeld of innovative research focused on the biological, phys-
ological and sociological differences between women and men
nd how such differences affect diseases and their diagnoses and
reatments, gender-based medicine shares with evidence-based
edicine the hypothesis that inaccuracies exist in the production
nd dissemination of knowledge, as well as in medical practice,
s regards rigor, transparency and subjective judgement.15,16 The
edia act as socialising agents and transmit messages that con-
ribute to the social construction of disease. The quantitative and/or
ualitative representation of both sexes in pharmaceutical adver-
isements is a focal point of interest in research on gender bias,11,12
ince if such representations are inconsistent with reality they may
einforce the perception that certain illnesses are associated with
he most frequently portrayed sex. Such is the case with adver-
isements for migraine treatments, in which images of women
redominate.17
Despite the social changes experienced by women and men
ince the 1970s, the view of medicine as a gendered organization
nd male-dominated culture has had a powerful effect on gen-
er imagery for women. This perspective has served to point to
edicine as a cultural system tending to reinforce a gender identity
ased on traditional sex roles of women in society.11 The accuracy
f knowledge transfer through pharmaceutical advertising is essen-
ial to avoid gender bias in medical practice and to achieve quality
rug prescription according to knowledge-based evidence.18
The aim of this study was to review the scientiﬁc literature
vailable on pharmaceutical advertising directed at health profes-
ionals (1998–2008) in order to determine whether gender biasnit. 2012;26(5):469–476
has decreased and the quality of information in pharmaceutical
advertising has improved over time. Clariﬁcation of these ques-
tions would allow health professionals to determine the current
credibility of this information. As quality information criteria, we
considered the ﬁndings of articles published on (a) the number,
validity and accessibility of bibliographic references provided in
pharmaceutical advertisements, and (b) the relationship between
the sexes portrayed in the advertisements and the sex-prevalence
of the diseases treated by the drugs advertised.
Methods
Original articles analyzing pharmaceutical advertising in medi-
cal journals and published between 1998 and 2008 were located
using Boolean search techniques in the bibliographic databases
PUBMED, Medline, Scopus, Sociological Abstracts, ERIC and LILACS.
The key words differed depending on the thesaurus of the biblio-
graphic source consulted. Thus, in PUBMED, Medline and Scopus,
the key words “Advertising and Medical Journals” and “Advertis-
ing and Drug Industry” were used, while in Sociological Abstracts
and ERIC, the key words were “Advertising and Medical Jour-
nals”, and “Advertising and Medication”. The search terms used
in LILACS were “Publicidad y Revistas Médicas” (“Advertising and
Medical Journals”) and “Publicidad de medicamentos e Industria far-
macéutica” (“Medicinal drug advertising and the Pharmaceutical
industry”). We  selected all articles containing these key words both
in their titles and in their abstracts. Articles without an abstract
were excluded since they are not usually original studies and tend
to be editorials, letters, practice guidelines or comments.
All original articles written in Spanish, English and Italian con-
cerning pharmaceutical advertising aimed at health professionals
and published in medical journals between 1998 and 2008 were
included.
Excluded from the study were those articles focusing on adver-
tising aimed directly at the consumer, advertising carried by
media other than medical journals or popular science magazines,
advertising ethics, or other marketing techniques used by the phar-
maceutical industry as tools for ongoing medical training through
sponsorship of courses and congresses.
A total of 1,715 articles were obtained, of which 552 did not
provide an abstract. Of the remaining 1,163 articles, 1,132 were
omitted in accordance with the exclusion criteria described in the
preceding paragraph (ﬁg. 1).
A content analysis was  carried out of the 31 original articles
ﬁnally selected, for which an information compilation protocol was
established and applied, comprising the following variables:
1) Scientiﬁc evidence in support of the advertising claims:
- Number of bibliographic references.
- Availability of the references in scientiﬁc bibliographic
databases.
- Consistency between the contents of the claims and the sci-
entiﬁc evidence published, measured through the agreement
between the content of the message and knowledge of the
drugs supported by scientiﬁc papers.
2) Sex-gender representation variables used in the analysis of
advertising images developed in the original articles:
- Number of women  and men  portrayed.
- Occupational roles represented at work by sex.
- Family roles represented in the domestic environment by sex.
3) Medicinal drugs advertised.
4) Journals from which advertising was  analyzed by the articlesreviewed.
5) Specialty of the medical journal containing the advertising.
6) Date of publication of the articles analyzed.
7) Country of origin of the journals analyzed.
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tigure 1. Selection process for assessing the quality and gender equity of pharma-
eutical advertising in medical journals (1998-2008).
) Type of research design used in the articles analyzed: quantita-
tive and/or qualitative.
) Period researched by the articles analyzed.
A content analysis of the above-mentioned variables was  carried
ut.
esults
Between 1998 and 2008, 31 original articles8,9,19–47 analyzed
he pharmaceutical advertising published in medical journals over
 period of 30 years (1975-2005) (Table 1). The number of adver-
isements analyzed per article ranged from 26 to 4,157.
Most of the advertising analyzed was  of European
rigin,19–23,27,29,32–35,38–45 particularly northern Europe22,26,34,35
nd England.29,33,34,38–40,45 Other advertising came from the
SA,24–31,33,36,38–42,44–46 Brazil,9,36 and Canada.27,33,39,40 By
omparing results from different articles, we noticed that the
ercentage of advertisements decreased from 50% in 1975
o approximately 30% in 2000.19,21,24,39,41 However, these
ifferences varied according to the journal and country of
rigin.19,21,24,28,29,35,39,41,44 British journals carried signiﬁcantly
ewer advertisements9,39 than those from the USA, which displayed
he highest levels of advertising pressure.9,39
Two varying approaches were used in advertising analysis.
n the one hand, an analysis of all pharmaceutical advertise-
ents published in medical journals and science magazines
as carried out,20,29,33,36,38,39,43 while on the other, the analy-
is focused exclusively on medicinal drugs used within speciﬁc
pecialities, such as antihypertensives and antilipids for cardio-
ascular problems, corticosteroids to treat respiratory problems,
edication for erectile dysfunction, psychotropics, analgesics and
ntibiotics.9,19,21–28,30–32,34,35,37,40,41,44–47
The most frequently made claim was that of the effectiveness of
he drug,16–18,24,26 followed by claims related to drug safety.19,20,27
Only eight articles (25.8%) presented longitudinal compar-
sons of advertising over a speciﬁed period.9,20,33,36,38,39,41,43
he remaining articles presented cross-sectional studies that
eviewed advertising published at a particular moment in
ime8,19,21–32,34,35,37,40,42,44–47 (Table 1).nit. 2012;26(5):469–476 471
The bibliographic references provided in pharmaceutical adver-
tising were easily accessible for consultation.26,46 In 2005, 65%
of bibliographic references were found in Medline, PsycInfo and
Google46 while in 1999 approximately 84% were found in databases
such as Medline, PubMed, WorldCat, California Digital Library and
Google.26
Fifteen articles9,19–21,25–27,29,32,36–38,41,42,46 examined the num-
ber of references provided in pharmaceutical advertising (Table 2).
There seems to be a temporal pattern, with an increasing tendency
to include references. Nevertheless, reference frequency varied
according to the journal’s country of origin and medical speciality.
For instance, articles analyzing advertising in Russian,42 Italian16
and Spanish21 journals included fewer references than those ana-
lyzing advertising in countries such as the UK, Netherlands, or the
USA.
However, in 50% of pharmaceutical advertisements, the ref-
erences provided as scientiﬁc support for the claims lacked
validity19,20,25,29,32,37 (Table 2) as these claims were insufﬁciently
supported by recorded scientiﬁc data, prescribing information, ran-
domized controlled trials or other research.25 Neither were they
supported by scientiﬁc evidence,19,20,37,44 as 44.4% of unsupported
claims recommended the drug for a patient group different to that
studied in the trial29 or were classiﬁed as ambiguous (vague: 54.3%;
emotive: 14.2%; non-clinical: 12.4%).32
Nine articles provided information on the sex of the peo-
ple appearing in the advertisements and the gender dimension
analysis categories used22,23,30,31,33,36,41,43,44 (Table 3). There was
a tendency to depict men  in paid productive roles, while
women appeared inside the home or in nonoccupational social
contexts.23,33,36,43,44 Moreover, while the articles that analyzed
advertising for cardiovascular disease medication coincided in their
ﬁndings that men  were given higher visibility,22,23,31 those that
focused on psychotropic pharmaceutical advertising concluded
that women were over-represented.23,33,36,43,44 The longitudinal
studies revealed that the closer the study period to the present
day, the greater the number of advertisements for antidepressant
treatments and the higher the percentage of women portrayed.33,43
The type of information used to promote medicinal drugs varied
among countries. An article that compared advertising in psychi-
atric journals in Brazil, the USA and the UK observed that journals
in the USA and the UK contained more scientiﬁc data about the
drug.9 More speciﬁcally, advertising in Brazilian psychiatric, pedi-
atric and general medicine journals lacked information on drug
interactions and adverse effects.9,36 Advertising carried by Rus-
sian journals on surgery, general medicine and cardiology also
contained scant data on drug interactions, adverse effects and
contraindications.42
Discussion
The articles that employed forward-speciﬁc longitudinal analy-
sis showed that from 1975 to 2005 the number of bibliographic
references used to support pharmaceutical advertising claims
increased.9,36,38,41 However, the accessibility, 26,46 as well as the
validity of the scientiﬁc references was limited.19,20,25,29,32,37 No
improvement was observed in advertising quality in developing
countries or when quality was  examined from a gender perspec-
tive. Articles carrying out a longitudinal analysis provided evidence
that the same traditional male-female roles were represented in the
ﬁrst years studied (1975, 1981, 1985) as well as in the later years
(1995, 2001).33,36,43 Gender bias was also identiﬁed in the studies
analyzing speciﬁc years during the same period30,31,44 and in the
following years (2001-2002, 2005).22,23
One of the limitations of this study is the small number of
articles found. Although the review period spanned 10 years,
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Table 1
Objective and main characteristics of the reviewed articles on pharmaceutical advertising in medical journals (1998-2008).
Author and year
of the article
Period of study Field and (number)
of medical journals
Objective of the study
Ahmed et al., 200430 1996-1998 Family/Internal Medicine (20)
Cardiology (14)
To determine if female and male physicians are equally represented in
cardiovascular advertising.
Ahmed et al., 200431 1996-1998 Family/Internal Medicine (20)
Cardiology (14)
To determine if female and male patients are equally likely to be featured in
cardiovascular advertising.
Cabral de Barros, 20048 2000-2001 Family/Internal Medicine (3) To evaluate advertising using the WHO  criteria for drug information as
parameters.
Carvalho et al., 200336 1985-7987
1987-1989
1999-2001
Psychiatry (4) To evaluate the inﬂuence of three regulations (“Export act”, “WHO criteria”,
“ANVISA”a) on drug advertisements.
Carvalho et al., 20059 1985-1989
1999-2001
Psychiatry (6) To compare the information contained in advertisements for psychoactive
drugs published in psychiatric journals in Brazil, USA and UK before the
“Export act”, “WHO criteria”, “ANVISA”a regulations.
Cooper and Schriger,
200326
1999 Psychiatry (1)
Neurology (1)
Surgery (1)
Emergency (1)
Obst/Gyn (1)
Pediatrics (1)
Family/Internal Medicine (3)
To characterize the quantity and quality of graphic information in all
pharmaceutical advertising.
Cooper et al., 200535 1999 Psychiatry (1)
Neurology (1)
Surgery (1)
Emergency (1)
Obst/Gyn (1)
Pediatrics (1)
Family/Internal Medicine (3)
To determinate the kinds of documents cited in support of claims made in
pharmaceutical advertising, and to assess the availability of these documents
to  healthcare practitioners.
Curry  and O’Brien, 200623 2001-2002 Family/Internal Medicine (3) To examine the gendered representations used to identify patients prone to
depression and heart disease.
Fortinguerra et al., 200719 2005 Pediatric (5) To evaluate whether the references cited in pharmaceutical advertisements
were evidence-based.
Friedman and Richter,
200624
2001 Family/Internal Medicine (2) To evaluate the inﬂuence of ethical guidelines by the International Committee
of  Medical Journal Editors on the frequency of advertisements in
peer-reviewed journals.
Gilad et al., 200527 2000 Family/Internal Medicine (6)
Surgery (6)
Pediatric (6)
Obst/Gyn (6)
To evaluate the quality of information on antibiotic drugs in medical journals.
Greving et al., 200720 1996-2004 Family/Internal Medicine (1) To determine how the pharmaceutical industry deals with evolving clinical
evidence in advertising claims for antihypertensive drugs.
Gutknecht, 200140 1999 Family/Internal Medicine (4) To evaluate whether the references in pharmaceutical advertisement were
evidence-based.
Jones  et al., 199945 1995-1997 Family/Internal Medicine (13) To determine whether the level of drug advertising is related to uptake of new
drugs by general practitioners.
Lankinen et al., 200432 2002 Family/Internal Medicine (4) To document the quality of the evidence base for marketing claims in
prescription drug advertising.
Lohiya, 200528 2004 Unspeciﬁed research journal
(28)
To quantify the amount and nature of pharmaceutical advertising in medical
journals.
Loke  et al., 200237 2000 Family/Internal Medicine (6) To evaluate whether the references in pharmaceutical advertisements were
evidence-based.
Lövdahl et al., 199944 1995 Psychiatry (4) To examine the gender display in Scandinavian and American advertising for
antidepressants.
Lövdahl  and Riska, 200043 1975/1985/1995 Psychiatry (4) To examine the construction of the relationship between gender identity and
mental disorders in Nordic psychotropic drug advertising.
Montgomery et al., 200847 2004 Family/Internal Medicine (4) To determine whether print advertisements for antihypertensive medications
promote quality prescribing.
Munce et al., 200433 1981/1991/2001 Psychiatry (3) To determine who is portrayed in psychotropic drug advertising over time.
Nelson  and Bloom, 200141 1975/2000 Urology (3) To compare advertising characteristics in 1975 with those in 2000.
Neumann et al., 200238 1990-1999 Family/Internal Medicine (6) To examine the frequency of economic messages in drug advertising in
medical journals.
Riera et al., 200721 2001 Family/Internal Medicine (3) To analyze the advertising message in drug advertisements.
Riska and Heikell, 200722 2005 Family/Internal Medicine (4) To examine the construction of heart disease candidates in advertising for
cardiovascular drugs.
Scott et al., 200434 1999-2001 Unspeciﬁed research journal (1) To examine the use of images to construct misleading associations between
diseases and drugs.
Spielmans et al., 200846 2005 Family/Internal Medicine (2)
Psychiatry (2)
To examine the accuracy and availability of sources cited in advertising for
psychiatric drugs.
Winkelen et al., 200625 2003-2004 Rheumatology (4) To evaluate whether the references in pharmaceutical advertisements were
evidence-based.
Villanueva et al., 200329 1997 Cardiology (2)
Family/Internal Medicine (4)
To evaluate whether the references cited in pharmaceutical advertisements
were evidence-based.
Vlassov et al., 200142 1998 Family/Internal Medicine (3)
Surgery (1) Cardiology (1)
To examine the adequacy of information in pharmaceutical advertising.
Weeks et al., 200239 1985/1990/1995/2000 Family/Internal Medicine (3) To quantify the frequency of advertising in peer-reviewed journals.
a Brazilian Health Surveillance Agency.
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Table  2
Frequency and quality of the information in advertisements and claims according to scientiﬁc references on drugs in the articles on pharmaceutical advertising reviewed
(1998-2008).
Authors Drugs advertised Country of journals
analyzed
N◦ of advertisements
analyzed
Claims or advertisements with
scientiﬁc references (%)
Claims not supported by
evidence-based medicinea
Spielmans et al.46 Psychotropic USA & Britain 69 45% -
Greving et al.20 Antihypertensives Holland 50 66% 35% not supported
Fontinguerra et al.19 All drugs Italy 70 26.1% 50% not supported
Riera  et al.21 All drugs Spain 609 21.2% -
Van  Winkelen et al.25 All drugs USA & Britain 84 - 49% poorly supported
Gilad  et al.27 Antibiotics vs. other drugs British, USA & Canada 779 Antibiotic drugs: 56.2%
Other drugs: 51.1%
-
Carvalho et al.9 Psychotropic Brazil USA & Britain 56 Brazil: 22.2% to 60%
USA: 28.5% to 70%
UK: 66.6% to 41.6%
-
Cooper and Schriger26 All drugs USA 484 71%
Lankinen et al.32 All drugs Finland 245 38% 81% ambiguous
Carvalho et al.36 Psychotropic Brazil 199 1986:15.4% to 22.6%
1988: 42.1% to 47.4% 2000:
55% to 58.8%
-
Villanueva et al.29 Antihypertensives Spain 287 13.2% 44.1% not supported.
Neumann et al.38 All drugs Britain & USA 237 56% to 70%. -
Loke  et al.37 All drugs Australia 174 56.8% 45% not supported
Nelson  and Bloom41 Antibiotics, erectile
dysfunction & analgesics
Britain &USA 574 USA: 15.1% to 25.8%
Europe: 25.9% to 58.7%
-
Vlassov  et al.42 All drugs Russia 207 2% -
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andomized controlled trials.
ew articles presented an empirical analysis of the information
ontained in pharmaceutical advertisements. Nevertheless, the
rticles analyzed cover 30 years of advertising (1975-2005). A
urther limitation is the diversity of the approaches used by the
ifferent authors in the analyses, with less than a third of the
rticles reporting a gender analysis or presenting results provid-
ng information on the sex of the consumer or the physicians
ortrayed in the advertisements. Moreover, most of the pharma-
eutical advertisements analyzed were related to cardiovascular
r psychotropic drugs and thus the possible existence of bias
n pharmaceutical advertising for other medicinal drugs was  not
etermined.
The advertising strategies erroneously over-represented one
ex without taking into account the sex-prevalence of the dis-
ase, which contributed to maintaining a gender bias in medical
nowledge and diagnostic and therapeutic decisions.22,23,31,33
his imbalance in therapeutic targets depicted in pharmaceu-
ical advertising was observed in advertising for both mental
ealth23,33,36,43,44 and cardiovascular disease medication.22,23,30,31
ccordingly, health professionals should maintain a critical
pproach when evaluating the credibility of the information con-
ained in pharmaceutical advertising. Likewise, health authorities
hould actively monitor the consequences of this type of adver-
ising strategy, which could be converting a private commercial
bjective into a social problem.
While a drug’s effectiveness is one of the main arguments used
n pharmaceutical advertising, some authors highlighted the lack of
pidemiological evidence, such as data on risk reduction in abso-
ute terms or on the number of patients treated, which could be
sed to support such claims.38,47 Indeed, as regards representa-
ions of male and female identity, Goffman claimed that these werey scientiﬁc evidence or poorly supported by data on ﬁle, prescribing information or
commonly represented through stereotyped images of what it
means to be a man  or a woman.48 Such representations may  reﬂect
the sexist construction of scientiﬁc knowledge49 which, in terms of
public health, has been criticized since the 1980s in the form of the
Gendering the Medicalization Thesis.11
The availability of scientiﬁc data is explicitly recommended in
the WHO  ethical criteria for medicinal drug promotion. However,
Carvalho showed that availability varied according to the country of
publication of the journal carrying the advertising. Speciﬁcally, less
information concerning interactions, adverse effects, precautions
or contraindications was provided in developing countries than in
developed countries.9
The longitudinal studies included in this review, accounting
for 25.8% of the total, showed that from 1975 to 2005, phar-
maceutical advertising validity increased in terms of providing
scientiﬁc data and references in support of the advertising claims
made. However, validity depended on the stage of develop-
ment of the journal’s country of origin.8,9,39,41 According to many
authors, such a lack of data can contribute to the medicalization of
the population’s health and encourage disease mongering,1,4,50–52
both of which would occur more readily in developing coun-
tries.
The WHO  medicinal drug promotion validity criteria basically
refer to scientiﬁc and epidemiological data, and to the accessi-
bility of documents supporting advertising claims.7 However, as
images are one of the main tools employed in advertising to trans-
mit  information and create and reﬂect collective perceptions, these
criteria should include the graphic representation of the consumer
as a further validity criterion. This would allow determination of
whether the sex or age frequency represented in the advertise-
ment is consistent with the epidemiological data, that is, the sex
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Table 3
Sex-gender representation of the consumers and medical professionals portrayed in medicinal drug advertising in the journals reviewed (1998-2008).
Author Drugs advertised Country of
journals
analyzed
No of
advertisements
analyzed
Year and percentage of women and
men at the advertisements studied
Occupational and family gender roles
represented in medicinal drug
advertisements
Riska and
Heikell22
Cardiovascular drugs Scandinavia 603 2005:
Men: 50%
Women: 25%
Both: 25%
Men and women are shown as a restored
character in their own private life.
Men: Kickboxing, biking with a helmet
with the name of the drug on it, walking
on  the beach with a dog, smiling in a pub.
Women: In the kitchen. Dress and face
covered with patches of whipped cream.
Curry  and
O’Brien23
Cardiovasc &
psychotropic drugs
Ireland 61 2001-2002:
Cardiovascular: 91.7% men
Psychotropic: 85.7%women
Users of cardiovascular drugs were
signiﬁcantly more likely than users of
antidepressants to be displayed in active
rather than passive roles (p < 0.001).
Ahmed  et al.30 Cardiovascular drugs USA 919 1996-1998:
Male physician: 83%
Female physician: 17%
Female physicians appearing in a top
position were less frequent than male
physicians. OR=95% CI=0.25 (0.09-0.68)
Ahmed  et al.31 Cardiovascular drugs USA 919 1996-1998:
Men: 80%
Women: 20%
Female patients had fewer average
appearances in advertisements than
males in top positions (0.82 vs 1.99; p =
0.02).
Munce  et al.33 Psychotropics drugs USA, Britain &
Canada.
161 Women  (1981-1991-2001):
Canada: 47% - 38% -80%
USA: 48% - 64% - 88%
UK: 63% - 50% - 40%
Occupational role: 81% men vs. Family
role: 90% women
Patient portrayed:
Women: Sleeping: 77%. At home and in
the garden category: 75%
Men: within the work category: 85%
Carvalho et al.36 Psychotropics drugs Brazil 199 1985-2000:
Ratio men/women:
Anxiolytic drugs: 1:2
Neuroleptic drugs: 6:1
Nelson and
Bloom41
All drugs in urologic
journals
Britain &USA 574 1975 – 2000:
Male urologists: 90%-76.47%
Female urologists: 10% -23.5%
Lövdahl and
Riska43
Psychotropic drugs Scandinavia 273 (Women vs. men):
1975 - 1985 - 1995
Denmark:
(34%-66%) - (75%-19%)-(66%-25%)
Finland:
(31%-69%) - (100% - 0) - (81% - 0)
Norway:
(100%-0) - (31% - 61%)-(100% -0)
Sweden:
(70%-27%)- (38%-52%) - (0 - 0)
1970s: Men  dominated the psychotropic
user category in Finnish and Danish
advertisements, while Norwegian and
Swedish advertisements portrayed
mental health problems as a female
concern.
1980s: As in the 1970s, advertisements
tended to show: Men  overworked on
account of an important position at work
needing a tranquilliser or hypnotic drug
to cope with the external pressure.
When women are shown at work they
are featured in a subordinate position
and smiling.
1990s: Use of the drug by women will
allow them to fulﬁl the expected
supportive female gender behavior.
Lövdahl et al.44 Psychotropic drugs Scandinavia &
USA
118 1995 (Women vs men  & both):
Denmark: 78% - 11% - 11%
Finland: 75% - 0 - 25%
Norway: 100% - 0 - 0
US
Sw
In pictures of both sexes together the
man is shown as the supporter of the
woman: women were depicted as the
ones needing assistance, while men
a
i
p
l
d
w
a
v
r
t
a
tnd age prevalence of the health problem for which a certain drug
s commercialized.
The spectrum of diseases for which the gender analysis of
harmaceutical advertising was performed and published was
imited to mental health and cardiovascular disease medicinal
rug promotion.22,23,30,31,33,36,43,44 These analyses conﬁrmed that
omen were consistently over-represented in psychotropic drug
dvertising,23,33,36,43,44 while the same was true for men  in cardio-
ascular disease medication advertising.22,23,30,31 However, scant
esearch has been published on whether this biased and par-
ial over-representation of one sex is repeated in pharmaceutical
dvertising for other types of medical treatments.
The under-representation of women in pharmaceutical adver-
ising for cardiovascular disease treatments correlates with theA: 38% - 0 - 62%
eden: 0 - 0 - 100%
symbolized either the physician, the
woman’s male partner, or the drug
(featured as a man) assisting her.
generation, dissemination and application of medical knowledge
on these diseases.15,16,49 This same tendency toward bias has been
observed in some clinical drug trials which are subsequently cited
in advertising, where either few women  are included in the trials
compared to the number who will eventually consume the drug
once commercialized, or information is provided which has not
been stratiﬁed by sex for efﬁcacy and effectiveness.53 Thus, when
concluding that the generation of new knowledge in medicine
focuses on male health and merely infers knowledge of female
health, Goffman’s thesis on advertising is in agreement with femi-
nist empiricism as applied to health.11
This double bias –generated by both science and advertising–
could undermine medical practice54 by helping to perpetuate a per-
ception that is inconsistent with data on the actual prevalence and
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ortality rate of the problem. For example, the higher representa-
ion of men  than women in cardiovascular medication advertising
s not consistent with the actual number of deaths from cardiovas-
ular disease within the European Union (56% women compared
ith 43% men).13
onclusions
Despite the diversiﬁcation of the role of women  over the last
ew years, the ﬁndings of the original papers reviewed reveal that
arity between men  and women in terms of the performance of
ocial tasks or functions is not reﬂected in the pharmaceutical
dvertisements analyzed.22,23,30,31,33,36,41,43,44 There is a consistent
endency to embody stereotyped images of both sexes. Speciﬁcally,
omen are portrayed in submissive or passive activities, such as
leeping33 and, in 2005, were still usually shown in traditional
ontexts and roles, such as cooking, shopping, or at home with
lothes and face covered in patches of whipped cream.22 Also, when
dvertising depicts men  with cardiovascular disease, the disease
s attributed to external factors, such as occupation.23 In con-
rast, pharmaceutical advertising for psychotropic drugs embodies
omen without a context, suggesting that such problems are gen-
rated by the woman herself.23
The ﬁndings obtained from the articles reviewed shows that the
uality of information on pharmaceutical advertising has improved
hrough the increase of bibliographic references during the study
eriod. However, some bibliographic references mentioned in the
dvertising could not be accessed, and there were some difﬁculties
elated to agreement between the content of the message and the
nowledge of drugs supported by scientiﬁc papers.
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